SLC34A2 Recombinant Monoclonal Antibody

說明書

中文名稱：

SLC34A2 Recombinant Monoclonal Antibody
貨號：

CSB-RA021581MA2HU
規格：

￥1320
圖片：
The Binding Activity of Human SLC34A2 with Anti-SLC34A2 Recombinant Antibody
Activity: Measured by its binding ability in a functional ELISA. Immobilized Human SLC34A2(CSB-MP021581HU1) at 2 μg/mL can bind Anti-SLC34A2 recombinant antibody. The EC₅₀ is 32.86-37.66 ng/mL.

The purity of SLC34A2 was greater than 95% as determined by SEC-HPLC
其他：

產品詳情
產品評價
相關產品
靶點詳情

產品詳情

產品描述：

CSB-RA021581MA2HU是針對SLC34A2蛋白研發的高特異性重組單克隆抗體。該抗體靶向的SLC34A2（溶質載體家族34成員2）是維持機體磷酸鹽穩態的關鍵轉運蛋白，在肺泡表面活性物質代謝、腸道營養吸收及腎臟磷重吸收等生理過程中發揮重要作用，其表達異常與多種代謝性疾病及呼吸系統病理改變密切相關。本產品經過嚴格的ELISA驗證，在1:5000至1:50000的寬泛稀釋范圍內均表現出優異的檢測靈敏度和抗原結合特異性，適用于體外樣本中SLC34A2蛋白的定量檢測及表達水平分析。科研人員可將其應用于磷酸鹽轉運機制研究、相關疾病模型構建及藥物靶點篩選等基礎研究領域，特別推薦用于細胞培養上清液、組織裂解液等實驗體系中的目標蛋白檢測，為探索SLC34A2在生理病理過程中的分子調控網絡提供可靠工具。
Uniprot No.：

O95436
基因名：

SLC34A2
別名：

SLC34A2 antibody; Sodium-dependent phosphate transport protein 2B antibody; Sodium-phosphate transport protein 2B antibody; Na(+)-dependent phosphate cotransporter 2B antibody; NaPi3b antibody; Sodium/phosphate cotransporter 2B antibody; Na(+)/Pi cotransporter 2B antibody; NaPi-2b antibody; Solute carrier family 34 member 2 antibody
反應種屬：

Human
免疫原：

Recombinant Human SLC34A2 protein
免疫原種屬：

Homo sapiens (Human)
標記方式：

Non-conjugated
克隆類型：

Monoclonal
抗體亞型：

hIgG1
純化方式：

Affinity-chromatography
克隆號：

7B6
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
產品提供形式：

Liquid
應用范圍：

ELISA

推薦稀釋比：

Application	Recommended Dilution
ELISA	1:5000-1:50000

Protocols：

ELISA Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產品評價

靶點詳情

功能：

May be involved in actively transporting phosphate into cells via Na(+) cotransport. It may be the main phosphate transport protein in the intestinal brush border membrane. May have a role in the synthesis of surfactant in lungs' alveoli.
基因功能參考文獻：
1. The upstream breakpoint lies in the same region as the breakpoint of a fused gene SLC34A2-ROS1, which encodes a constitutive kinase in the lung cancer cell line HCC78 and nonsmall-cell lung cancer (NSCLC), suggesting that the deletion in this family is a hot spot for recombination, not only in cancer samples with somatic mutation, but also in PAM patients with germline genetic defects of SLC34A2. PMID: 30262706
2. SLC34A2 plays a crucial promoting role in colorectal cancer development. PMID: 29653487
3. Studied expression of solute carrier family 34 member 2 (SLC34A2/NaPi2b) in epithelial ovarian cancer using monoclonal antibody MX35 and immunohistochemistry. Different staining intensities were observed in different grades of epithelial ovarian cancer. PMID: 28464843
4. Low SLC34A2 expression is associated with non-small cell lung cancer. PMID: 26910912
5. SLC34A2 has an important role in promoting proliferation and tumorigenicity of BC. PMID: 28151475
6. SLC34A2 was down-regulated in osteosarcoma patients.SLC34A2 interacted with PTEN, and decreased the phosphorylation of PI3K and AKT, which inactivated the PI3K/AKT signaling pathway. PMID: 28777670
7. High expression of SLC34A2 was identified in about 2/3 patients and correlated with significantly better patient's overall survival. Epidermal growth factor receptor mutations were detected in about 53% of patients with no statistically significant difference to patient's overall survival. Anaplastic lymphoma kinase rearrangement was found in 8 out of 175 patients, harboring this abnormality leads to shorter overall survi PMID: 28720066
8. we elucidated that miR-939 exerted its function mainly through inhibiting SLC34A2/Raf/MEK/ERK pathway, which is activated in GC. Multivariate analysis identified miR-939, SLC34A2, and their combination as independent indicators for poor prognosis and tumor recurrence in GC patients. PMID: 28114937
9. a novel role of SLC34A2 inbreast cancer stem cells (BCSCs) state regulation and establishes a rationale for targeting the SLC34A2/PI3K/AKT/SOX2 signaling pathway for breast cancer therapy. PMID: 28381172
10. Knockdown of SLC34A2 inhibits proliferation. PMID: 28281971
11. Our work sheds new light on the nature of the state of lung cancer stem cell-like cells and the role of SLC34A2 in the tumorigenicity of these cells PMID: 26846105
12. our data indicated that SLC34A2 could exert significantly suppressive effects on tumorigenesis and progression of NSCLC. SLC34A2 might provide new insights for further understanding the early pathogenesis of human non-small cell lung cancer PMID: 26156586
13. SLC34A2 might be associated with the initiation and progression of lung adenocarcinoma PMID: 25017204
14. Data indicate that humanized monoclonal antibody Rebmab200 and murine monoclonal antibody MX35 monoclonal antibodies had similar specificity for sodium phosphate transporter NaPi2b. PMID: 23936189
15. investigation revealed that the c.910A > T mutation in the SCL34A2 gene was responsible for pulmonary alveolar microlithiasis (PAM) patients in China PMID: 23164546
16. identified 2 cases of pulmonary alveolar microlithiasis(PAM) with new mutations of SLC34A2 gene; identified the NaPi-IIb in a aortic valve; hypothesize that mutations in SLC34A2 may play a role in development of aortic valve calcification and arteriosclerosis PMID: 22336687
17. a comprehensive analysis indicates that SCL34A2 is the only gene of the several phosphate transporters genes whose expression differentiates normal from carcinoma samples, suggesting it might exert a major role in ovarian carcinomas. PMID: 22553815
18. The performed study revealed that SLC34A2 gene exhibited the most distinct change in expression and may become a molecular marker of papillary thyroid cancer PMID: 17091453
19. study provides the data on the pattern of NaPi2b expression and cellular localization in breast, lung and ovarian cancers PMID: 21956469
20. Upregulation of SLC34A2 gene expression in well-differentiated tumors may reflect cell differentiation processes during ovarian cancerogenesis and could serve as potential marker for ovarian cancer diagnosis and prognosis. PMID: 21716206
21. There was a significantly increased gene expression of SLC34A2 (normal tissues: 6.71+/-0.77; tumour tissues: 10.29+/-0.80) among breast cancer tissues compared with normal tissues. PMID: 21036732
22. In human lung alveolar epithelial cells, the content of calcium and phosphate in cell supernatant decreased with increased amount of SLC34A2 mRNA. PMID: 19134407
23. study describes mutations in SLC34A 2 gene in an inbred Turkish family with three siblings diagnosed with pulmonary alveolar microlithiasis(PAM); findings suggest that impaired activity of the SLC34A2 gene may be responsible for familial PAM PMID: 20046000
24. A novel mutation in exon 8 of the SLC34A2 gene were associated with pulmonary alveolar microlithiasis in Chinese pedigree. PMID: 20017296
25. The current study was performed to characterize the minimal promoter region and transcriptional factor(s) necessary to activate gene expression of NaPi-IIb in human intestinal cells. PMID: 15458926
26. Study identified a pulmonary alveolar microlithiasis locus by homozygosity mapping to 4p15, then identified, by a candidate-gene approach, the gene responsible for the disease as SLC34A2, which is involved in phosphate homeostasis in several organs. PMID: 16960801
27. Mutations in the SLC34A2 gene that abolish normal gene function cause pulmonary alveolar microlithiasis. PMID: 17095743
28. The monoclonal antibodies were shown to recognize specifically transiently overexpressed and endogenous NaPi2b in commonly used immunoassays. PMID: 18724815
29. SLC34A2 is associated with sodium-lithium countertransport activity and blood pressure PMID: 19119262
30. The gene responsible for PAM, SLC34A2, has been identified. It encodes a type IIb sodium-dependent phosphate transporter, the function of which provides an insight into the pathogenesis of this disease. PMID: 19617834
顯示更多

收起更多
相關疾病：

Pulmonary alveolar microlithiasis (PALM)
亞細胞定位：

Membrane; Multi-pass membrane protein.
蛋白家族：

SLC34A transporter family
組織特異性：

Highly expressed in lung. Also detected in pancreas, kidney, small intestine, ovary, testis, prostate and mammary gland. In lung, it is found in alveolar type II cells but not in bronchiolar epithelium.
數據庫鏈接：

HGNC: 11020

OMIM: 265100

KEGG: hsa:10568

STRING: 9606.ENSP00000371483

UniGene: Hs.479372

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human
WDR5 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
VIM Recombinant Monoclonal Antibody

Applications: ELISA, IHC, IF

Species Reactivity: Human